|
Press Room
2007 Press Releases
TSX:V - IXS
NASD OTC:BB: IXSBF
September 18, 2007
InNexus Biotechnology CEO to Give Keynote Presentation at 18th Annual Wall Street Analyst Forum
British Columbia, Canada - September 18, 2007 - InNexus Biotechnology Inc. (OTCBB: IXSBF, TSX: IXS.V), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, is pleased to announce that Jeff Morhet, Chairman and CEO, will be a guest speaker on BNN – Business News Network’s Power Breakfast segment which highlights top officials of important and powerful companies in Canadian and US business.
During the month of September BNN’s Power Breakfast will highlight profitable and interesting companies on the TSX Venture Exchange. The segment will air Wednesday, September 26th, on the morning show, The Street – with Linda Sims, and will run at 8:50am ET.
BNN-Business News Network is Canada’s only television service devoted exclusively to business, finance and the markets. It is available throughout Canada on cable, satellite and wireless systems and is wholly owned by CTV Inc., a division of CTVglobemedia.
About DXL™ Technology
DXL™ technology works by integrating self-binding peptides into monoclonal antibodies, potentiating target binding. Modified antibodies "cluster" upon engaging the target receptor site, resulting in greater "molecular mass" at the point of association. This may facilitate cancer cell destruction in a target dependent manner by increasing apoptosis, antibody dependent cell cytotoxicity and complement-dependent cytotoxicity. In addition, DXL™ antibodies have significantly extended dissociation rates, as measured by surface plasmon resonance. To learn more about InNexus' DXL™ technology, please visit www.ixsbio.com.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Contact
InNexus Biotechnology Inc.
Dr. Thomas Kindt, Chief Scientific Officer
480-862-7500
The Investor Relations Group
Investor Relations:
Christine Berni/Joe Triunfo, 212-825-3210
cberni@investorrelationsgroup.com
jtriunfo@investorrelationsgroup.com
|
|
|
